FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895572113> ?p ?o ?g. }

• W2895572113 endingPage "956" @default.
• W2895572113 startingPage "946" @default.
• W2895572113 abstract "Anti-PD-(L)1 can provide overall survival (OS) benefits over conventional treatments for patients with many different cancer types. However, the long-term outcome of cancer patients responding to these therapies remains unknown. This study is an exploratory study that aimed to describe the long-term survival of patients responding to anti-PD-(L)1 monotherapy across multiple cancer types.Patients and Methods: Data from patients treated with an anti-PD-(L)1 monotherapy in a phase I trial at Gustave Roussy were retrospectively analyzed over a period of 5 years. All cancer types (n = 19) were included. Clinical and biological factors associated with response, long-term survival, and secondary refractory disease were studied.Among 262 eligible patients, the overall objective response rate was 29%. The median progression-free survival of responder patients (RP) at 3 months was 30 months, and the median OS of RP was not reached after a median follow-up of 34 months. In RPs, 3- and 5-year OS percentages were 84% and 64%, respectively. No death occurred in the 21 complete responders (CR) during the overall follow-up. However, many partial responders (PR) showed subsequent tumor relapses to treatment. Long responders (response ≥2 years) represented 11.8% of the overall population. These findings should be validated in further prospective studies.There are currently no differences in therapeutic strategies between CRs and PRs to anti-PD-(L)1. We found a striking difference in OS between these two types of responses. Our results are in favor of evaluating patient stratification strategies and intensification of treatments when tumor lesions of a partial responder to immunotherapy stop improving.See related commentary by Cohen and Flaherty, p. 910." @default.
• W2895572113 created "2018-10-12" @default.
• W2895572113 creator A5008444865 @default.
• W2895572113 creator A5011984137 @default.
• W2895572113 creator A5021624793 @default.
• W2895572113 creator A5023804337 @default.
• W2895572113 creator A5028436035 @default.
• W2895572113 creator A5028963681 @default.
• W2895572113 creator A5030174263 @default.
• W2895572113 creator A5030924742 @default.
• W2895572113 creator A5031446684 @default.
• W2895572113 creator A5032462496 @default.
• W2895572113 creator A5034376000 @default.
• W2895572113 creator A5056132643 @default.
• W2895572113 creator A5060793722 @default.
• W2895572113 creator A5063737641 @default.
• W2895572113 creator A5065206480 @default.
• W2895572113 creator A5080101109 @default.
• W2895572113 creator A5082291642 @default.
• W2895572113 creator A5086593040 @default.
• W2895572113 creator A5090082356 @default.
• W2895572113 date "2019-02-01" @default.
• W2895572113 modified "2023-09-30" @default.
• W2895572113 title "Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation" @default.
• W2895572113 cites W1982488143 @default.
• W2895572113 cites W1982906652 @default.
• W2895572113 cites W1999482469 @default.
• W2895572113 cites W2080682920 @default.
• W2895572113 cites W2097995306 @default.
• W2895572113 cites W2101653483 @default.
• W2895572113 cites W2119147717 @default.
• W2895572113 cites W2120426523 @default.
• W2895572113 cites W2124427232 @default.
• W2895572113 cites W2128035403 @default.
• W2895572113 cites W2135808990 @default.
• W2895572113 cites W2150048477 @default.
• W2895572113 cites W2164090407 @default.
• W2895572113 cites W2222086386 @default.
• W2895572113 cites W2238503624 @default.
• W2895572113 cites W2296049142 @default.
• W2895572113 cites W2299181842 @default.
• W2895572113 cites W2329974159 @default.
• W2895572113 cites W2463547628 @default.
• W2895572113 cites W2465860350 @default.
• W2895572113 cites W2481467115 @default.
• W2895572113 cites W2493541962 @default.
• W2895572113 cites W2529484692 @default.
• W2895572113 cites W2529904548 @default.
• W2895572113 cites W2541574334 @default.
• W2895572113 cites W2557336488 @default.
• W2895572113 cites W2558219863 @default.
• W2895572113 cites W2562305489 @default.
• W2895572113 cites W2567334173 @default.
• W2895572113 cites W2592144107 @default.
• W2895572113 cites W2597018043 @default.
• W2895572113 cites W2748446166 @default.
• W2895572113 cites W2767789104 @default.
• W2895572113 doi "https://doi.org/10.1158/1078-0432.ccr-18-0793" @default.
• W2895572113 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30297458" @default.
• W2895572113 hasPublicationYear "2019" @default.
• W2895572113 type Work @default.
• W2895572113 sameAs 2895572113 @default.
• W2895572113 citedByCount "90" @default.
• W2895572113 countsByYear W28955721132019 @default.
• W2895572113 countsByYear W28955721132020 @default.
• W2895572113 countsByYear W28955721132021 @default.
• W2895572113 countsByYear W28955721132022 @default.
• W2895572113 countsByYear W28955721132023 @default.
• W2895572113 crossrefType "journal-article" @default.
• W2895572113 hasAuthorship W2895572113A5008444865 @default.
• W2895572113 hasAuthorship W2895572113A5011984137 @default.
• W2895572113 hasAuthorship W2895572113A5021624793 @default.
• W2895572113 hasAuthorship W2895572113A5023804337 @default.
• W2895572113 hasAuthorship W2895572113A5028436035 @default.
• W2895572113 hasAuthorship W2895572113A5028963681 @default.
• W2895572113 hasAuthorship W2895572113A5030174263 @default.
• W2895572113 hasAuthorship W2895572113A5030924742 @default.
• W2895572113 hasAuthorship W2895572113A5031446684 @default.
• W2895572113 hasAuthorship W2895572113A5032462496 @default.
• W2895572113 hasAuthorship W2895572113A5034376000 @default.
• W2895572113 hasAuthorship W2895572113A5056132643 @default.
• W2895572113 hasAuthorship W2895572113A5060793722 @default.
• W2895572113 hasAuthorship W2895572113A5063737641 @default.
• W2895572113 hasAuthorship W2895572113A5065206480 @default.
• W2895572113 hasAuthorship W2895572113A5080101109 @default.
• W2895572113 hasAuthorship W2895572113A5082291642 @default.
• W2895572113 hasAuthorship W2895572113A5086593040 @default.
• W2895572113 hasAuthorship W2895572113A5090082356 @default.
• W2895572113 hasBestOaLocation W28955721132 @default.
• W2895572113 hasConcept C121332964 @default.
• W2895572113 hasConcept C121608353 @default.
• W2895572113 hasConcept C126322002 @default.
• W2895572113 hasConcept C141071460 @default.
• W2895572113 hasConcept C142424586 @default.
• W2895572113 hasConcept C143998085 @default.
• W2895572113 hasConcept C2778715236 @default.
• W2895572113 hasConcept C2779134260 @default.
• W2895572113 hasConcept C2908647359 @default.

• next